SPY001

Spyre Therapeutics, Inc. · Phase 2 active Small molecule

At a glance

Generic name	SPY001
Also known as	SPY001-001
Sponsor	Spyre Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SPY001 CI brief — competitive landscape report
SPY001 updates RSS · CI watch RSS
Spyre Therapeutics, Inc. portfolio CI